论文部分内容阅读
目的:研究分析溴化异丙托品治疗慢性支气管哮喘的临床疗效。方法:随机选取2010年2月-2012年4月来我院就诊的27例慢性支气管哮喘患者作为观察组,另外抽取27例作为对照组,对照组采取常规安慰剂治疗,观察组在常规治疗的基础上给予溴化异丙托品。观察并记录好两组患者在用药前及用药后2d、4d、6d及后期3个月内的特征、临床症状、一秒钟用力肺活量(FEV1)等。结果:两组患者连续用药5d后,观察组的总有效率明显高于对照组,组间差异具有统计学意义(p均<0.05)。结论:治疗慢性支气管哮喘可采用溴化异丙托品,其效果明显,作用时间持久,且对支慢性气管患者的气道起到明显的扩张作用,有利于改善肺部功能,轻微副作用可减少患者痛苦,值得推广和应用,具有一定的临床价值。
Objective: To study the clinical efficacy of ipratropium bromide in the treatment of chronic bronchial asthma. Methods: Twenty-seven patients with chronic bronchial asthma who were admitted to our hospital from February 2010 to April 2012 were randomly selected as the observation group and another 27 as the control group. The control group was treated with conventional placebo. The patients in the observation group were treated with routine treatment Based on the given ipratropium bromide. The characteristics, clinical symptoms, forced vital capacity per second (FEV1) before and 2d, 4d, 6d and 3 months after treatment were observed and recorded in both groups. Results: The total effective rate of the observation group was significantly higher than that of the control group after 5 days continuous administration, the difference was statistically significant (all P <0.05). CONCLUSION: Ipratropium bromide may be used to treat chronic bronchial asthma. The effect is obvious and the action time lasts long. It plays a significant role in the expansion of the airway of patients with chronic bronchial asthma, which is helpful to improve lung function and reduce the slight side effects Patients suffering, it is worth promoting and application, has a certain clinical value.